SCHEMBL1329650

SCHEMBL1329650

CCc1cccc(CC)c1-c1cc(C)c(CN2CCc3ccccc3C2)c(C)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.46
C5AR1 P21730 6/20 0.44
CD44 P16070 1/20 0.44
KDM4E B2RXH2 3/20 0.43
KMT2A Q03164 2/20 0.43
GAA P10253 2/20 0.43
HTT P42858 2/20 0.43
MAPT P10636 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
POLB P06746 1/20 0.42
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
PRMT5 O14744 2/20 0.41
WDR77 Q9BQA1 2/20 0.41
MAPK1 P28482 1/20 0.41
SPR P35270 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4417669 0.89 C5AR1 (0.42) LMNAC5AR1CD44KDM4EKMT2A
SCHEMBL1329134 0.89 LMNA (0.44) LMNAC5AR1CD44KDM4EKMT2A
SCHEMBL1329410 0.88 C5AR1 (0.54) LMNAC5AR1KDM4EKMT2AHTT
SCHEMBL4417666 0.86 KMT2A (0.45) LMNAC5AR1CD44KDM4EKMT2A
SCHEMBL1327356 0.85 C5AR1 (0.46) LMNAC5AR1CD44KDM4EKMT2A
SCHEMBL4825967 0.83 LMNA (0.41) LMNAC5AR1CD44KDM4EKMT2A
SCHEMBL1327505 0.83 CD44 (0.46) LMNAC5AR1CD44KDM4EKMT2A
SCHEMBL1327907 0.83 C5AR1 (0.48) LMNAC5AR1KDM4EHTTMAPT
SCHEMBL1327354 0.82 C5AR1 (0.44) LMNAC5AR1CD44KDM4EKMT2A
SCHEMBL2137925 0.82 C5AR1 (0.43) C5AR1KDM4EKMT2AMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110281837-A1 3-SUBSTITUTED-6-ARYL PYRIDINES HUTCHINSON ALAN J (US) 2011-11-17 US disclosed
US-7863454-B2 3-substituted-6-aryl pyridines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2011-01-04 US disclosed
US-20090176980-A1 3-Substituted-6-Aryl Pyridines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2009-07-09 US disclosed
US-7342115-B2 Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology NEUROGEN CORPORATION (US) 2008-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281837-A1 3-SUBSTITUTED-6-ARYL PYRIDINES C3AR1, C5AR1, C5AR2 LMNA 3672/4885C5AR1 2/4885CD44 4561/4885
US-20090176980-A1 3-Substituted-6-Aryl Pyridines C3AR1, C5AR1, C5AR2 LMNA 3672/4885C5AR1 2/4885CD44 4561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.